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Introduction
Like people, cells are born, they live for a time and (with a few 
notable exceptions) they die. Indeed, cell death is an essential 
part of tissue renewal. The linkage between cell death and birth 
is bi-directional. An unexpected loss of cells accelerates growth 
of similar cells in a healing process that is essential for functional 
homeostasis, whereas the need to replace senescent cells with 
new cells requires programmed elimination of older, damaged or 
less functional tissue. An appreciation of these two pathophysi-
ological contexts led to the classical paradigm of cell death being 
either mandated or elective. Mandated cell death (often referred 
to as “necrosis”) is typically the consequence of trauma or tissue 
damage, and has therefore been anthropomorphically labeled cell 
murder; like murder, mandated cell death is not tidy. The cellular 
response to lethal injury involves cell swelling, loss of membrane 
integrity and release of chemical mediators that can cause col-
lateral damage. From the victim’s (cell/tissue/organ) perspective, 
this form of cell death is random and therefore unplanned. For 
the organism there is a crime scene to clean and cellular corpses to 
remove. Critical functions normally performed by the murdered 
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Programmed cell elimination is an important pathological 
mediator of disease. Multiple pathways to programmed cell 
death have been delineated, including apoptosis, autophagy 
and programmed necrosis. Cross-talk between the signaling 
pathways mediating each process has made it difficult to 
define specific mechanisms of in vivo programmed cell 
death. For this reason, many “apoptotic” diseases may involve 
other death signaling pathways. recent advances in genetic 
complementation using mouse knockout models are helping 
to dissect apoptotic and necrotic cell death in different 
pathological states. The current state of research in this area 
is reviewed, focusing upon new findings describing the 
role of programmed necrosis induced by the mitochondrial 
permeability transition in mouse models of heart failure and 
diabetes.
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cells are interrupted by their absence, and can be further dis-
rupted by first responders (i.e., inflammation).
By contrast, the conventional view is that elective cell death 
is much cleaner for all concerned. This is certainly the case for 
apoptotic cell death, as originally conceived by Vogt in the 19th 
century and more strictly defined by Kerr, Wyllie and Curie in 
1972.1 The best anthropomorphism for apoptosis is probably 
“assisted cell suicide” as there is extensive molecular and cellular 
infrastructure that supports this form of elective cell termination. 
Apoptotic cell death is the deliberate result of processes initiated 
in response to developmental cues or external factors that are, 
themselves, non-lethal. In either case, the cell decides to remove 
itself, packs up its constituent proteins, organelles and DNA for 
easy removal and essentially “turns off and fades away”. As a 
consequence of this planning and effort, the untoward collateral 
effects associated with mandated cell death are largely avoided.
Elective cell death is essential for normal tissue development 
and homeostasis, and is therefore tightly regulated. Apoptotic 
cell death is an evolutionarily conserved process resulting from 
cascade activation of caspase cysteine proteases downstream of 
cytokine death receptors (the extrinsic apoptosis pathway) or 
transcriptionally and post-translationally regulated mitochon-
drial-localized Bcl2 family members (the intrinsic apoptosis 
pathway; reviewed in ref. 2). Dysregulation of programmed cell 
death perturbs normal tissue homeostasis and is implicated in 
cancer (too little apoptosis), Alzheimer disease (inappropriate 
apoptosis) and other chronic degenerative conditions.3-5
In recent years, this comfortable and straightforward para-
digm of mandated versus elective cell death has been complicated 
by the recognition of multiple apoptotic and non-apoptotic path-
ways for programmed cell elimination. In particular, it is clear 
that cell death also occurs via a phenomenon of “programmed 
necrosis”, which is elective like apoptosis, but untidy like necrosis. 
To extend the previous anthropmorphisms, programmed necro-
sis is neither cell murder, nor assisted cell suicide, but is more like 
the cell figuratively throwing itself in front of an oncoming bus. 
The result is elective cell elimination in a manner that is func-
tionally disruptive and activates inflammatory mechanisms. The 
molecular and biochemical pathways that regulate, initiate and 
mediate programmed cell necrosis are only now being defined, 
and it likely to be mediated by multiple non-apoptotic mecha-
nisms leading to abrupt metabolic shut-down. It is ironic that 
John Foxton Ross Kerr, the father of modern apoptosis, originally 
used the term “programmed cell necrosis” to describe his concept 
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MPTP dissipates the normal mitochondrial pH gradient and 
inner membrane electrochemical potential (Δψ
m
) that are 
required for ATP production through oxidative phosphoryla-
tion.20 MPTP opening therefore reverses ATP synthesis, and the 
mitochondrion becomes a net ATP consumer. The loss of cellular 
ATP subsequent to MPTP opening ignites a cascade of metabolic 
dysfunction that can ultimately lead to cell necrosis.
Another consequence of MPTP opening is osmotic mito-
chondrial swelling that disrupts outer mitochondrial membranes, 
permitting cytochrome c to be released into the cytosol from 
the mitochondrial inter-membranous space. Although MPTP-
dependent cytochrome c release can activate the apoptotic 
caspase cascade, cell death by apoptosis requires ATP that is criti-
cally deficient after the mitochondrial permeability transition. 
Thus, cell death subsequent to the mitochondrial permeability 
transition proceeds via metabolic shutdown and programmed 
necrosis, rather than apoptosis. Because cytochrome c release and 
its sequelae occur in both apoptosis and MPTP-dependent pro-
grammed cell necrosis, they do not reliably indicate one or the 
other cell death pathway.
The structural components of the MPTP are not completely 
clear.21,22 Core MPTP elements consist of the voltage-depen-
dent anion channel (VDAC), the adenine nucleotide transloca-
tor (ANT) and cyclophilin D (CyP-D). The VDAC was long 
considered to be an essential component of the MPTP,23-25 but 
genetic models have convincingly refuted this notion; the VDAC 
is dispensable for both Bcl2 family member-mediated apoptosis 
and MPTP-dependent necrosis.26 Likewise, gene ablation studies 
in mice showed that mitochondria lacking ANT can undergo 
permeability transition.27 ANTs may function as phosphate- and 
calcium-sensitive MPTP regulators. In contrast, three indepen-
dent groups have reported that genetic ablation of CyP-D is suf-
ficient to eliminate the mitochondrial permeability transition 
without affecting conventional mitochondrial-mediated apopto-
sis.6,28,29 For this reason, genetic Ppif ablation has been used to 
demonstrate the role of MPTP opening and programmed cell 
necrosis in mouse models of Alzheimer’s disease, muscular dys-
trophy, diabetes mellitus and heart failure.30-33
Our studies of MPTP-mediated programmed β-cell death 
in diabetes used a genetic mouse model, the Pdx1 hemizygous 
mouse.32 PDX1 (pancreatic and duodenal homeobox factor 1; 
also called insulin promoter factor 1, IPF1) is a necessary tran-
scription factor for pancreas development. Loss of function 
human Pdx1 mutations are linked with pancreatic agenesis, 
heritable maturity onset diabetes of the young and type 2 diabe-
tes.34-36 Likewise, germ-line homozygous Pdx1 gene ablation in 
mice produces lethal pancreatic agenesis,37 whereas heterozygous 
germ-line or β-cell specific Pdx1 null mutations result in a dia-
betes phenotype.38,39 Several cellular mechanisms have been pro-
posed for loss of insulin-producing pancreatic β-cells in the Pdx1 
deficient model of diabetes, including decreased proliferation,40 
and increased programmed cell death through apoptosis and 
autophagy.13,41,42 The prevailing opinion has been that increased 
β-cell death, and not decreased proliferation, is the more impor-
tant mechanism, with apoptosis most often implicated.14 As 
indicated above however, the standard markers of apoptosis do 
of natural cell death. The various terms currently being used to 
describe non-apoptotic elective cell death (programmed necrosis, 
regulated necrosis, necroptosis) continue to be confusing as none 
are mechanistically based.6,7
Apoptosis and programmed necrosis are mediated by distinct 
signaling pathways, but the two processes can be difficult to dif-
ferentiate in vivo. There is no specific histochemical marker for 
programmed necrosis. Dystrophic calcification and complement 
activation have been used to identify necrotic tissue, but these 
markers do not differentiate between standard and programmed 
tissue necrosis. On the other hand, conventional markers for 
apoptosis (cytochrome c release, activate caspases and TUNEL 
labeling) do not exclude programmed necrosis because mitochon-
drial swelling and outer membrane rupture that are the primary 
cause of programmed necrosis secondarily release cytochrome 
c into the cytosol. Although this activates apoptosis signaling, 
reversal of ATP production in cells undergoing necrosis prevents 
the orderly (and energy-requiring) dismantling of the cellular 
machinery, and so they don’t die of apoptosis. Concomitant 
activation of apoptotic markers in cells undergoing programmed 
necrosis seems likely to have implicated apoptosis in diseases 
where programmed necrosis is a primary mechanism of elective 
cell elimination.
Here, new findings linking programmed necrosis mediated 
via the mitochondrial permeability transition with diabetes and 
heart failure are explored. The striking benefits that accrued from 
genetic interruption of programmed necrosis in mouse models of 
these two human conditions should prompt a re-evaluation of 
widely held notions that apoptotic cell death is the major effector 
of pathological cell loss.
Pancreatic β-cell Deficiency in Diabetes;  
Apoptosis or Programmed Necrosis?
A simple operational definition of diabetes is: any condition in 
which endogenous insulin production and secretion are insuf-
ficient to meet metabolic demands. Mechanistically, this includes 
conditions where there is an absolute paucity of insulin in indi-
viduals of normal body mass (type 1 diabetes),8 or where there is 
an abundance of insulin in individuals whose need is still greater, 
due to increased body mass and/or insulin resistance (type 2 dia-
betes).9,10 Insulin is produced exclusively by β-cells located within 
the pancreatic Islets of Langerhans, and these cells have the abil-
ity to undergo hyperplasia in response to metabolic stress.11 Both 
forms of diabetes are causally linked to (absolute or relative) 
β-cell deficiency,12 and in many instances attributed to increased 
β-cell apoptosis.13-15 However, targeting β-cell apoptosis has 
either been incompletely successful in preventing diabetes,16 or 
has unmasked latent oncogenic potential.17 These results point 
to a parallel programmed death pathway in pancreatic β-cells.18
We recently used genetic complementation in a mouse diabe-
tes model to interrogate the role of programmed β-cell necrosis 
caused by opening of the mitochondrial permeability transition 
pore (MPTP). The MPTP is a non-selective pore in the mito-
chondrial inner membrane that opens in response to increased 
local calcium concentration.19 Proton diffusion through the 
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Together, these studies implicate MPTP-mediated β-cell necrosis 
as an important component of pathological programmed β-cell 
death caused by Pdx1 deficiency, and support a co-equal role 
for conventional apoptosis through the mitochondrial pathway 
(Fig. 1). Prevention of diabetes with only partial normalization 
of β-cell mass in Pdx1-deficient mice lacking functional MPTP 
likely reflects physiological pancreatic insulin reserve.
Programmed Cardiac Myocyte Death in Heart Failure
Because adult cardiac myocytes are terminally differentiated and 
replication-deficient, normal tissue homeostatic mechanisms do 
not apply. Although these cells proliferate during cardiac devel-
opment, shortly after birth the rate of cell division drops to lev-
els that are difficult to quantify, but are certainly inadequate for 
meaningful tissue regeneration. Because there is no cardiac myo-
cyte replacement, there is no normal level of programmed cardiac 
myocyte death. Even after tissue injury or under conditions of 
not discriminate between apoptosis 
and programmed necrosis. Therefore, 
it was possible that programmed β-cell 
necrosis in Pdx1 insufficiency had been 
mis-identified as apoptosis based on 
findings of cytochrome c release and 
β-cell TUNEL positivity. We examined 
this possibility in cultured mouse insu-
linoma-derived β-cells (MIN6 cells), 
using shRNA to suppress Pdx1 expres-
sion, TUNEL as a measure of apoptosis 
signaling, rhodamine 123 to measure 
integrity of the MPTP and propidium 
iodide to assess cell death in a pathway-
independent manner.32 As expected, 
Pdx1 suppression increased TUNEL 
positivity and β-cell death. Importantly, 
it also opened β-cell MPTPs, which is 
not a direct effect of apoptosis. To deter-
mine if MPTP opening was a primary 
or secondary effect of Pdx1 suppression, 
we treated the cells with cyclosporin A, 
a pharmacological inhibitor of CyP-D 
(the essential protein for MPTP open-
ing). Cyclosporin A prevented MPTP 
opening and significantly reduced 
Pdx1-deficient β-cell TUNEL positiv-
ity and death. This result suggested that 
MPTP opening could be responsible for 
as much as half of cultured β-cell death 
induced by Pdx1 deficiency.
We used genetic complementa-
tion with ppif null mice (the ppif gene 
encodes CyP-D) to assess the role of 
MPTP-induced β-cell necrosis in 
murine diabetes caused by Pdx1 haplo-
insufficiency. Pancreatic islets of Pdx1 
haplo-insufficient mice are character-
istically small, with strikingly reduced numbers of insulin-con-
taining β-cells. Eliminating functional MPTPs through ppif 
ablation increased islet size and decreased TUNEL labeling. 
We also stained the pancreata for complement 9, a component 
of the complement membrane attack complex that is part of the 
inflammatory response to cell necrosis. Complement 9 staining 
was increased in Pdx1 haplo-insufficient islets, but was normal-
ized by concomitant ppif ablation. This histological “rescue” was 
observed in both adult and neonatal pancreata, revealing a role for 
MPTP-mediated programmed β-cell necrosis during embryonic 
development and for β-cell homeostasis in the adult pancreas.
Finally, we determined the consequences of preventing MPTP-
mediated programmed β-cell necrosis on the diabetic phenotype 
of adult Pdx1 deficient mice. Diabetes in this model is mani-
fested by decreased circulating insulin and increased blood glu-
cose levels measured either at baseline or in response to an acute 
glucose challenge. Ablation of ppif in Pdx1 haplo-insufficient 
mice almost completely normalized both of these parameters. 
Figure 1. Schematic depiction of programmed β-cell death pathways implicated in diabetes caused 
by Pdx1 haplo-insufficiency. Deficiency of transcription factor Pdx1 likely alters gene expression, ac-
tivating pathways that induce apoptosis via mitochondrial outer membrane permeabilization (left) 
and programmed necrosis via the mitochondrial permeability transition (right). Pancreatic β-cell 
autophagy is also induced by Pdx1 insufficiency, but its role in programmed cell death is currently 
unclear.
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and physiological stimuli for programmed cardiomyocyte 
elimination.
Based on the above results, we hypothesized that Nix (and the 
programmed cardiac myocyte death it produces) mediates pro-
gression to heart failure in pressure overload cardiac hypertrophy. 
To test this idea, we created cardiac-specific Nix gene knockout 
mice, subjected them to surgical pressure overload and compared 
cardiomyocyte TUNEL labeling, ventricular remodeling and 
cardiac function to identically pressure overloaded hearts of mice 
with intact Nix genes. Cardiac Nix knockout mice exhibited 
only half the typical rate of cardiomyocyte TUNEL positivity 
and myocardial fibrosis after pressure overloading and exhibited 
almost no ventricular dilation, wall thinning or decrease in con-
tractile systolic function.55 These data identified Nix as a critical 
inducible factor mediating programmed cardiac myocyte death 
in pressure overload hypertrophy and established a causal role for 
Nix in adverse ventricular remodeling and development of heart 
failure.
Delineation of Multiple Nix-Stimulated  
Cell Death Pathways
Like all pro-apoptotic Bcl2 family members, Nix stimulates 
caspase-dependent apoptosis resulting from mitochondrial outer 
membrane permeabilization. In cardiac myocytes and other cell 
types, Nix localizes to mitochondria and induces cytochrome c 
release that is followed by caspase activation and oligonucleoso-
mal DNA degradation.50 However, we recently observed that only 
~80% of transfected Nix localizes to mitochondria; the remain-
der is localized to endoplasmic reticulum (ER) or the analogous 
structure in cardiac myocytes, sarcoplasmic reticulum (SR).56 We 
further observed a direct relationship between cardiac myocyte 
Nix levels and cardiomyocyte SR calcium stores: Nix overexpres-
sion increased SR calcium content by ~20%, whereas Nix gene 
ablation decreased SR calcium content by ~20%. Although SR 
calcium release is a critical regulator of myocyte contraction, we 
postulated that SR-localized Nix did not meaningfully regulate 
cardiac contractility. Rather, we felt that SR calcium might play a 
role in Nix-mediated cell death. Indeed, restoration of normal SR 
calcium levels in Nix knockout mice by genetic complementation 
with the phospholamban null mouse reversed the cardio-protec-
tive effects observed with Nix ablation, increasing programmed 
cardiomyocyte death, exaggerating the cardiomyopathy and 
increasing mortality. These results linked SR calcium to pro-
grammed cardiac myocyte death and heart failure produced by 
Nix.
We considered that reticular-mitochondrial calcium cross-
talk57 stimulated by SR-localized Nix could induce the “necrotic” 
pathway to programmed cardiomyocyte death. If this were the 
case, cardiomyocyte “apoptosis” we and others have reported 
based on TUNEL staining might instead be a secondary effect of 
mitochondrial rupture after MPTP opening, as we had observed 
in pancreatic β-cells (see above). However, little was known about 
the role of calcium and MPTP opening in programmed cardiac 
myocyte death. While calcium is used to stimulate MPTP open-
ing in laboratory studies using isolated mitochondria, it has been 
non-lethal stress, programmed cardiac myocyte elimination is 
pathological. Nevertheless, apoptosis is observed in cardiac myo-
cytes of failing, ischemic and pressure overloaded hearts, and is 
implicated in progression to cardiomyopathy.43 Indeed, a genetic 
program for programmed cell death is one of the hallmarks of the 
“compensatory” hypertrophic reaction to cardiac overload.44,45
Using microarray-based RNA profiling of Gq transgenic 
mice, our laboratory first described a genetic program for car-
diac myocyte death in hypertrophied hearts. Gαq (the alpha 
sub-unit of the heterotrimeric Gq signaling protein) transduces 
signaling through cardiac myocyte hypertrophy pathways stim-
ulated by angiotensin II, α1-adrenergic and endothelin recep-
tors. The Gq mouse expresses four to five times the normal 
amount of myocardial Gαq, resulting in ligand-independent 
Gq signaling and autonomous cardiac hypertrophy with many 
of the pathological characteristics of pressure overload hyper-
trophy (but without pressure overload).46 Shortly thereafter we 
further described progression to dilated cardiomyopathy medi-
ated by Gαq-stimulated cardiomyocyte apoptosis,47,48 suggest-
ing a link between cardiomyocyte hypertrophic growth and 
programmed death. Specifics of this linkage were established 
by transcriptional profiling, which identified increased levels of 
several death pathway genes in Gq hearts.49,50 One of these death 
genes encoded Nix (also called BNip3L), a member of the small 
BH3-like only subclass of mitochondrial-targeted Bcl2 apopto-
sis regulating proteins.
Because they are the sites of action for Nix and other Bcl2 
family proteins, mitochondria have been called the “gatekeep-
ers” of programmed cell death.51 Bax and Bak are the essential 
pore-forming proteins that permeabilize mitochondrial outer 
membranes, leading to cytochrome c release and intrinsic apop-
tosis signaling. Pore-formation by Bax and Bak is facilitated by 
pro-apoptotic BH3 domain-only factors, including Nix/BNip3L 
that we identified in the heart. Nix and other BH3-only factors 
hetero-dimerize with anti-apoptotic Bcl2 and Bclx
l
, which pre-
vents mitochondrial pore formation by Bax and Bak.2 Dynamic 
regulation of Nix, Bax, Bak and other pro- or anti-apoptotic Bcl2 
family proteins is characteristic of heart failure (reviewed in ref. 
52). A protein kinase C/SP1-dependent mechanism for tran-
scriptional upregulation appears to be responsible for increased 
Nix gene expression in cardiac hypertrophy.53
We used cardiac transgenesis to determine the in vivo con-
sequences of Nix upregulation in hearts, independent of Gq, 
cardiac hypertrophy or any hemodynamic stress or cardiac 
injury. Nix expression was directed specifically to cardiac myo-
cytes using the MYH6 promoter, which is transcriptionally 
activated only after birth. The result of post-natal cardiac-spe-
cific Nix expression was mice that were born normal, but suc-
cumbed to progressive dilated cardiomyopathy on the seventh 
to tenth day of life. TUNEL staining was positive in 15–20% 
of cardiac myocytes, implicating massive programmed car-
diac myocyte death in this form of fulminant heart failure.50 A 
subsequent study in which Nix was conditionally expressed in 
the heart revealed synergism between Nix and pressure over-
load stress for inducing apoptotic heart failure in adult hearts,54 
uncovering functional coordination by Nix of transcriptional 
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hypertrophy decompensation and the progression to overt heart 
failure.
Conclusions
It may be time to revise our perceptions of the role for apoptosis 
in chronic disease. In general, apoptosis seems to be a good thing. 
It is an essential feature of normal embryonic tissue development 
and adult tissue homeostasis. When normal apoptotic mecha-
nisms are interrupted by natural or experimental mutation, the 
consequences of unopposed cell growth can be tumor or malig-
nancy. Because the assays used to define apoptosis are not specific 
for that mechanism, “apoptosis” has been implicated and vili-
fied in variety of chronic diseases associated with abnormal cell 
death. An increased appreciation that all programmed cell death 
is not apoptotic, and especially for the role of the mitochondrial 
suggested that the MPTP is relatively calcium insensitive in vivo 
due to stabilization by cytosolic factors.58 Because dual Nix local-
ization to mitochondria and reticulum confounds experimen-
tation designed to identify calcium-stimulated non-apoptotic 
death pathways induced by reticular Nix, we created mitochon-
dria-directed and ER/SR-directed Nix mutants and analyzed 
their effects after recombinant expression in Nix null embryonic 
fibroblasts.33 Mitochondrial-directed Nix stimulated cell death 
marked by caspase activation, but normal Δψ
m
, i.e., apoptosis. In 
contrast, reticular-directed Nix stimulated cell death preceded by 
MPTP opening and dissipation of Δψ
m
, i.e., necrosis, but in which 
caspase activation attributed to cytochrome c release after MPTP 
opening and outer mitochondrial membrane rupture was also 
observed. Using the same experimental design as in our diabetes 
studies, we found that pharmacological (cyclosporin A) or genetic 
(CyP-D, Ppif ablation) inhibition of the MPTP prevented cell 
death induced by reticular Nix, but not by mitochondrial Nix.33 
Importantly, apoptosis induced by mitochondrial-directed Nix 
required Bax or Bak, whereas programmed cell necrosis induced 
by reticular-directed Nix showed no requirement for Bax and 
Bak. These results demonstrated that mitochondrial-directed 
Nix specifically activates conventional Bax/Bak-dependent mito-
chondrial pathway apoptosis, whereas reticular-directed Nix spe-
cifically induces MPTP-dependent programmed cell necrosis by 
increasing reticular calcium concentration and calcium delivery 
to mitochondria (Fig. 2).
To determine the relative contribution of Nix-mediated 
apoptosis versus programmed necrosis to in vivo heart failure we 
translated the above experimental design to the in vivo murine 
system and created cardiac-specific conditional transgenic mice 
expressing mitochondrial-directed or reticular-directed Nix 
mutants.33 The in vivo dilated cardiomyopathy phenotypes 
and extent of cardiac myocyte TUNEL labeling (which does 
not differentiate between apoptosis and programmed necrosis) 
were similar in mitochondrial-directed and reticular-directed 
Nix mutant mice. However, cardiac myocyte necrosis visualized 
by anti-complement 9 staining was observed only in reticular-
directed mutant Nix mice. Transmission electron microscopy 
likewise revealed mitochondrial swelling, matrix degeneration 
and outer membrane disruption only in cardiomyocytes from 
reticular-directed Nix mice. A causal link between MPTP 
opening in reticular-directed Nix-induced cardiac myocyte 
death was established by concomitant ablation of ppif (encod-
ing CyP-D) in the Nix mutant cardiomyopathy models. ppif 
ablation prevented cardiomyocyte death (TUNEL labeling) 
and complement 9 staining in reticular-directed Nix expressing 
mice, normalizing mitochondrial ultrastructure and preventing 
the dilated cardiomyopathy. In contrast, ppif ablation did little 
to improve the apoptotic cardiomyopathy produced by mito-
chondrial-directed Nix. These findings show that an impor-
tant aspect of Nix-mediated cell death is programmed necrosis 
mediated by SR-mitochondrial crosstalk. As other reports have 
implicated cardiac myocyte or sarcoplasmic reticular cal-
cium levels in cardiac injury and heart failure progression,59-61 
MTPT opening stimulated by reticular-mitochondrial calcium 
cross-talk may play a greater role than previously suspected in 
Figure 2. Schematic depiction of multiple Nix-induced pathways for 
cell death in heart failure. Transcriptionally upregulated Nix localizes 
either to mitochondria, where it interacts with Bax and Bak to induce 
apoptosis via outer membrane permeabilization, or to calcium-contain-
ing sarcoplasmic reticulum (Sr), where it increases calcium stores and 
activates the mitochondrial permeability transition pore (MPTP) inde-
pendent of Bax and Bak. Mitochondrial disruption subsequent to MPTP 
opening leads to metabolic shutdown and death via programmed 
necrosis.
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As our understanding of programmed cell death continues to 
evolve, the following aspects deserve attention: First, researchers 
and reviewers should bear in mind that conventional markers of 
apoptosis are not specific for apoptosis. Mechanistic implications 
from TUNEL labeling may be no more valid than those from 
propidium iodide staining. Both label dead or dying cells with-
out unambiguously defining a particular mechanistic pathway. 
Even observation of apoptotic bodies, oligonucleosomal DNA 
cleavage, and nuclear chromatin condensation (each of which is 
widely considered pathognomonic for apoptosis) does not exclude 
concomitant activation of alternate pathways to programmed 
cell elimination. Complicating this issue, there is no satisfactory 
marker for programmed cell necrosis, although complement acti-
vation is more abundant with necrosis than apoptosis. Second, we 
need to determine if there is a physiological role for MPTP open-
ing and programmed cell necrosis, or if it is a purely pathological 
process. Finally, we need to identify the proximal causes of cell 
death after MPTP opening. Certainly ATP depletion starts the 
process, but is there a role for mitochondrial release of reactive 
oxygen species and calcium in addition to metabolic shutdown 
in programmed cell necrosis? Further examination of these issues 
may suggest novel approaches to interdict programmed cell death 
in disease.
permeability transition and programmed necrosis, may reveal 
that non-apoptotic programmed cell death plays a major role in 
pathological programmed cell elimination. Chronic diseases in 
which MPTP-dependent programmed cell death has been impli-
cated include Alzheimer’s disease,30 muscular dystrophy,31 amyo-
trophic lateral sclerosis,62 heart failure,33 and diabetes.32 It is likely 
that this list will expand further.
The dichotomy between apoptotic and programmed necrotic 
cell death is mechanistically useful, but is almost certainly blurred 
in the in vivo context. As noted previously, a cell may initiate the 
process for apoptosis via permeabilization of mitochondrial outer 
membranes by Bax and Bak, but if there is insufficient ATP to 
complete the process, the ultimate consequence may be necrotic 
death from metabolic shutdown, or even a state of severe, but 
non-lethal dysfunction that some have describes as a “zombie” 
cell. It is also likely that some mitochondria within a single cell 
will undergo outer membrane permeabilization (apoptosis), oth-
ers will undergo the permeability transition (necrosis), and some 
fraction will continue to function normally for at least a while. 
Under these circumstances, the determination of whether the cell 
will die, and the mechanism for programmed cell elimination, 
would be the aggregate of all relevant external factors and intra-
cellular conditions.
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